Neumonía grave por sars-cov-2: Análisis transversal y de supervivencia en adultos de 18 a 59 años atendidos en la unidad de terapia intensiva de un hospital de tercer nivel en Manizales, Colombia

Tablas, Gráficos

Autores:
Tipo de recurso:
Fecha de publicación:
2025
Institución:
Universidad de Caldas
Repositorio:
Repositorio Institucional U. Caldas
Idioma:
spa
OAI Identifier:
oai:repositorio.ucaldas.edu.co:ucaldas/26800
Acceso en línea:
https://repositorio.ucaldas.edu.co/handle/ucaldas/26800
https://repositorio.ucaldas.edu.co
Palabra clave:
610 - Medicina y salud
3. Ciencias Médicas y de la Salud
SARS-COV-2
Neumonía
Covid-19
Epidemiología
Pandemia
Mortalidad
Virología
Epidemiología
Adulto
Rights
License
https://creativecommons.org/licenses/by/4.0/
id REPOUCALDA_ab296f02373aeabfb6e8ac0557dfb6fa
oai_identifier_str oai:repositorio.ucaldas.edu.co:ucaldas/26800
network_acronym_str REPOUCALDA
network_name_str Repositorio Institucional U. Caldas
repository_id_str
dc.title.none.fl_str_mv Neumonía grave por sars-cov-2: Análisis transversal y de supervivencia en adultos de 18 a 59 años atendidos en la unidad de terapia intensiva de un hospital de tercer nivel en Manizales, Colombia
title Neumonía grave por sars-cov-2: Análisis transversal y de supervivencia en adultos de 18 a 59 años atendidos en la unidad de terapia intensiva de un hospital de tercer nivel en Manizales, Colombia
spellingShingle Neumonía grave por sars-cov-2: Análisis transversal y de supervivencia en adultos de 18 a 59 años atendidos en la unidad de terapia intensiva de un hospital de tercer nivel en Manizales, Colombia
610 - Medicina y salud
3. Ciencias Médicas y de la Salud
SARS-COV-2
Neumonía
Covid-19
Epidemiología
Pandemia
Mortalidad
Virología
Epidemiología
Adulto
title_short Neumonía grave por sars-cov-2: Análisis transversal y de supervivencia en adultos de 18 a 59 años atendidos en la unidad de terapia intensiva de un hospital de tercer nivel en Manizales, Colombia
title_full Neumonía grave por sars-cov-2: Análisis transversal y de supervivencia en adultos de 18 a 59 años atendidos en la unidad de terapia intensiva de un hospital de tercer nivel en Manizales, Colombia
title_fullStr Neumonía grave por sars-cov-2: Análisis transversal y de supervivencia en adultos de 18 a 59 años atendidos en la unidad de terapia intensiva de un hospital de tercer nivel en Manizales, Colombia
title_full_unstemmed Neumonía grave por sars-cov-2: Análisis transversal y de supervivencia en adultos de 18 a 59 años atendidos en la unidad de terapia intensiva de un hospital de tercer nivel en Manizales, Colombia
title_sort Neumonía grave por sars-cov-2: Análisis transversal y de supervivencia en adultos de 18 a 59 años atendidos en la unidad de terapia intensiva de un hospital de tercer nivel en Manizales, Colombia
dc.contributor.none.fl_str_mv Franco Betancur, oliva
Hoyos-Londoño, Monica
Betancurth Loaiza, Diana Paola
dc.subject.none.fl_str_mv 610 - Medicina y salud
3. Ciencias Médicas y de la Salud
SARS-COV-2
Neumonía
Covid-19
Epidemiología
Pandemia
Mortalidad
Virología
Epidemiología
Adulto
topic 610 - Medicina y salud
3. Ciencias Médicas y de la Salud
SARS-COV-2
Neumonía
Covid-19
Epidemiología
Pandemia
Mortalidad
Virología
Epidemiología
Adulto
description Tablas, Gráficos
publishDate 2025
dc.date.none.fl_str_mv 2025-02-06
2026-04-14T23:34:22Z
2026-04-14T23:34:22Z
dc.type.none.fl_str_mv Trabajo de grado - Especialización
http://purl.org/coar/resource_type/c_18ws
Text
info:eu-repo/semantics/report
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_93fc
dc.identifier.none.fl_str_mv https://repositorio.ucaldas.edu.co/handle/ucaldas/26800
Universidad de Caldas
Repositorio institucional de la Universidad de Caldas
https://repositorio.ucaldas.edu.co
url https://repositorio.ucaldas.edu.co/handle/ucaldas/26800
https://repositorio.ucaldas.edu.co
identifier_str_mv Universidad de Caldas
Repositorio institucional de la Universidad de Caldas
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv Fadaka AO, Remaliah N, Sibuyi S, Bolaji Adewale O, Bakare OO, Akanbi MO, et al. Understanding the epidemiology, pathophysiology, diagnosis and management of SARS-CoV-2. Journal of International Medical Research [Internet]. [cited 2021 Jun 1];48(8):1–23. Available from: https://us.sagepub.com/en-us/nam/open-access-at-sage
China Responds Slowly, and a Pig Disease Becomes a Lethal Epidemic - The New York Times [Internet]. [cited 2021 Jun 23]. Available from: https://www.nytimes.com/2019/12/17/business/china-pigs-african-swine-fever.html
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Internet]. 2020 Mar 12 [cited 2021 Aug 1];579(7798):270. Available from: /pmc/articles/PMC7095418/
The origin of COVID: Did people or nature open Pandora’s box at Wuhan? - Bulletin of the Atomic Scientists [Internet]. [cited 2021 Aug 1]. Available from: https://thebulletin.org/2021/05/the-origin-of-covid-did-people-or-nature-open-pandoras-box-at-w uhan/
WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet]. [cited 2021 Aug 1]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at -the-media-briefing-on-covid-19---11-march-2020
Wang H, Paulson KR, Pease SA, Watson S, Comfort H, Zheng P, et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet [Internet]. 2022 Apr 16 [cited 2022 Jul 24];399(10334):1513–36. Available from: http://www.thelancet.com/article/S0140673621027963/fulltext
Schmidt C. COVID-19 long haulers. Nat Biotechnol [Internet]. 2021 Jul 13 [cited 2021 Aug 1]; Available from: http://www.nature.com/articles/s41587-021-00984-7
Sun C, Dyer S, Salvia J, Segal L, Levi R. Worse Cardiac Arrest Outcomes During The COVID-19 Pandemic In Boston Can Be Attributed To Patient Reluctance To Seek Care. https://doi.org/101377/hlthaff202100250. 2021 May 26;40(6):886–95.
Vista de Carta desde mi ventana Una fatalista reflexión pandémica [Internet]. [cited 2021 Aug 1]. Available from: https://revistas.uis.edu.co/index.php/revistasaluduis/article/view/11554/11068
Tackling the mental health impact of the COVID-19 crisis: An integrated, whole-of-society response [Internet]. [cited 2021 Aug 1]. Available from: https://www.oecd.org/coronavirus/policy-responses/tackling-the-mental-health-impact-of-the-cov id-19-crisis-an-integrated-whole-of-society-response-0ccafa0b/
O’Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 2020 590:7844 [Internet]. 2020 Nov 2 [cited 2022 Jul 24];590(7844):140–5. Available from: https://www.nature.com/articles/s41586-020-2918-0
Russell TW, Hellewell J, Jarvis CI, Zandvoort K Van, Abbott S, Ratnayake R, et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. Eurosurveillance [Internet]. 2020 Mar 26 [cited 2022 Jul 30];25(12):2000256. Available from: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.12.2000256
Staerk C, Wistuba T, Mayr A. Estimating effective infection fatality rates during the course of the COVID-19 pandemic in Germany. BMC Public Health [Internet]. 2021 Dec 1 [cited 2022 Aug 15];21(1). Available from: /pmc/articles/PMC8178670/
Marschner IC. Estimating age-specific COVID-19 fatality risk and time to death by comparing population diagnosis and death patterns: Australian data. BMC Medical Research Methodology 2021 21:1 [Internet]. 2021 Jun 21 [cited 2022 Jul 30];21(1):1–10. Available from: https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-021-01314-w
Hong D, Lee S, Choi YJ, Moon S, Jang Y, Cho YM, et al. The age-standardized incidence, mortality, and case fatality rates of COVID-19 in 79 countries: a cross-sectional comparison and their correlations with associated factors. Epidemiol Health [Internet]. 2021 [cited 2023 Feb 15];43. Available from: /pmc/articles/PMC8611321/
Team F. Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. The Lancet [Internet]. 2022 Apr 16 [cited 2023 Feb 15];399(10334):1469–88. Available from: http://www.thelancet.com/article/S0140673621028671/fulltext
Pastorino R, Pezzullo AM, Villani L, Causio FA, Axfors C, Contopoulos-Ioannidis DG, et al. Change in age distribution of COVID-19 deaths with the introduction of COVID-19 vaccination. Environ Res [Internet]. 2022 Mar 1 [cited 2022 Jul 14];204(Pt C). Available from: https://pubmed.ncbi.nlm.nih.gov/34748775/
Mattar S, Martinez-Bravo C, Rivero R, Contreras H, Faccini-Martínez ÁA, Guzman-Teran C, et al. Epidemiological and viral features of a cohort of SARS-CoV-2 symptomatic and asymptomatic individuals in an area of the Colombian Caribbean. Ann Clin Microbiol Antimicrob [Internet]. 2020 [cited 2021 Jun 4];19:58. Available from: https://doi.org/10.1186/s12941-020-00397-5
Gautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, et al. Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol [Internet]. 2020;16(12):1159–84. Available from: https://doi.org/10.1080/1744666X.2021.1847640
Adams SH, Park MJ, Schaub JP, Brindis CD, Irwin CE. Medical Vulnerability of Young Adults to Severe COVID-19 Illness—Data From the National Health Interview Survey. Journal of Adolescent Health. 2020 Sep 1;67(3):362–8.
Shahid Z, Kalayanamitra R, McClafferty B, Kepko D, Ramgobin D, Patel R, et al. COVID-19 and Older Adults: What We Know [Internet]. Vol. 68, Journal of the American Geriatrics Society. Blackwell Publishing Inc.; 2020 [cited 2021 May 9]. p. 926–9. Available from: https://doi.org/10.1038/s41591-020-
Ioannidis JPA. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bull World Health Organ. 2021 Jan 1;99(1):19-33F. doi: 10.2471/BLT.20.265892. Epub 2020 Oct 14. PMID: 33716331; PMCID: PMC7947934.
Sorci G, Faivre B, Morand S. Explaining among-country variation in COVID-19 case fatality rate. Scientific Reports 2020 10:1 [Internet]. 2020 Nov 3 [cited 2021 Sep 28];10(1):1–11. Available from: https://www.nature.com/articles/s41598-020-75848-2
Lu Y, Huang Z, Wang M, Tang K, Wang S, Gao P, et al. Clinical characteristics and predictors of mortality in young adults with severe COVID-19: a retrospective observational study. Ann Clin Microbiol Antimicrob [Internet]. 2021 Dec 1 [cited 2021 May 9];20(1):3. Available from: https://doi.org/10.1186/s12941-020-00412-9
Siu YL, Teoh KT, Lo J, Chan CM, Kien F, Escriou N, Tsao SW, Nicholls JM, Altmeyer R, Peiris JS, Bruzzone R, Nal B. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J Virol [Internet]. 2008 Nov 15 [cited 2021 Aug 19];82(22):11318–30. Available from: https://pubmed.ncbi.nlm.nih.gov/18753196/
Tracking SARS-CoV-2 variants [Internet]. [cited 2021 Aug 19]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A, Kimura I, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 2022 603:7902 [Internet]. 2022 Feb 1 [cited 2023 Feb 4];603(7902):706–14. Available from: https://www.nature.com/articles/s41586-022-04474-x
Plotkin S, Robinson JM, Cunningham G, Iqbal R, Larsen S. The complexity and cost of vaccine manufacturing - An overview. Vaccine [Internet]. 2017 Jul 24 [cited 2021 Sep 29];35(33):4064–71. Available from: https://pubmed.ncbi.nlm.nih.gov/28647170/
Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, De Ridder D, Petrovic D, Schrempft S, Marcus K, Yerly S, Arm Vernez I, Keiser O, Hurst S, Posfay-Barbe KM, Trono D, Pittet D, Gétaz L, Chappuis F, Eckerle I, Vuilleumier N, Meyer B, Flahault A, Kaiser L, Guessous I. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet [Internet]. 2020 Aug 1 [cited 2021 Aug 31];396(10247):313–9. Available from: https://pubmed.ncbi.nlm.nih.gov/32534626/
Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med [Internet]. 2021 Jan 1 [cited 2021 Sep 29];174(1):69–79. Available from: https://pubmed.ncbi.nlm.nih.gov/32941052/
Wong SCY, Kwong RT, Wu TC, Chan JWM, Chu MY, Lee SY, Wong HY, Lung DC. Risk of nosocomial transmission of coronavirus disease 2019: an experience in a general ward setting in 40 Hong Kong. J Hosp Infect [Internet]. 2020 Jun 1 [cited 2021 Sep 29];105(2):119–27. Available from: https://pubmed.ncbi.nlm.nih.gov/32259546/
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis [Internet]. 2020 Aug 1 [cited 2021 Sep 1];71(15):732–9. Available from: https://pubmed.ncbi.nlm.nih.gov/32150618/
Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. https://doi.org/101056/NEJMoa2012410 [Internet]. 2020 May 7 [cited 2021 Sep 30];382(25):2411–8. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa2012410
Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA [Internet]. 2020 Jun 23 [cited 2021 Sep 1];323(24):2493–502. Available from: https://jamanetwork.com/journals/jama/fullarticle/2766117
Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci [Internet]. 2020 [cited 2021 Sep 29];50(SI-1):611–9. Available from: https://pubmed.ncbi.nlm.nih.gov/32293834/
JP J. Monoclonal Antibody for Patients with Covid-19. N Engl J Med [Internet]. 2021 Mar 25 [cited 2021 Sep 29];384(12):1170–1. Available from: https://pubmed.ncbi.nlm.nih.gov/33534967/
Spinner CD, Gottlieb RL, Criner GJ, López JRA, Cattelan AM, Viladomiu AS, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA [Internet]. 2020 Sep 15 [cited 2021 Sep 29];324(11):1048–57. Available from: https://jamanetwork.com/journals/jama/fullarticle/2769871
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study - Merck.com [Internet]. [cited 2021 Oct 11]. Available from: https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-re duced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-forpatients-with-mild-or-moderat/
Zhang J, Rao X, Li Y, Zhu Y, Liu F, Guo G, et al. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. Ann Intensive Care [Internet]. 2021 Dec 1 [cited 2022 Jan 10];11(1). Available from: https://pubmed.ncbi.nlm.nih.gov/33420963/
Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med [Internet]. 2020 Mar 1 [cited 2021 Dec 14];8(3):267–76. Available from: https://pubmed.ncbi.nlm.nih.gov/32043986/
Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med [Internet]. 2021 Mar 18 [cited 2022 Jan 10];384(11):1015–27. Available from: https://pubmed.ncbi.nlm.nih.gov/33523609/
Bewick V, Cheek L, Ball J. Statistics review 12: Survival analysis. Crit Care [Internet]. 2004 Oct [cited 2023 Feb 21];8(5):389. Available from: /pmc/articles/PMC1065034/
Horwitz LI, Jones SA, Cerfolio RJ, Francois F, Greco J, Rudy B, et al. Trends in COVID-19 Risk-Adjusted Mortality Rates. J Hosp Med [Internet]. 2021 Feb 1 [cited 2023 Feb 6];16(2):90–2. Available from: https://pubmed.ncbi.nlm.nih.gov/33147129/
Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Intern Med [Internet]. 2020 Nov 1 [cited 2023 Feb 6];180(11):1436–47. Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2768602
Kreier F. Wide-ranging genetic study of severe COVID finds common risk factors. Nature [Internet]. 2022 Mar 10 [cited 2022 Mar 22]; Available from: https://www.nature.com/articles/d41586-022-00677-4
Changing the COVID-19 Case Definition - UK Health Security Agency [Internet]. [cited 2022 Feb 5]. Available from: https://ukhsa.blog.gov.uk/2022/02/04/changing-the-covid-19-case-definition/
Edwin F, Alvarado P, Milena S, Fuentes A, Malo DC, Leidy S, et al. Instituto Nacional de Salud. Anexo. Instructivo para la vigilancia en salud pública intensificada de infección respiratoria aguda asociada al nuevo coronavirus 2019 (COVID-19) [Internet]. 2020 [cited 2021 Apr 18]. Available from: https://www.atlantico.gov.co/images/stories/adjuntos/ salud/1-Anexo__Instructivo_COVID.pdf.
Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nature Medicine 2022 28:8 [Internet]. 2022 Jul 25 [cited 2023 Feb 7];28(8):1706–14. Available from: https://www.nature.com/articles/s41591-022-01909-w
Who, HQ, Ddi, Dna, Cat. INTERNATIONAL GUIDELINES FOR CERTIFICATION AND CLASSIFICATION (CODING) OF COVID-19 AS CAUSE OF DEATH Based on ICD International Statistical Classification of Diseases.
Corman Victor M, Landt Olfert, Kaiser Marco, Molenkamp Richard, Meijer Adam, Chu Daniel KW. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;… [Internet]. [cited 2023 Feb 8]. Available from: https://www.eurosurveillance.org/docserver/fulltext/eurosurveillance/25/3/eurosurv-25-35.pdf?e xpires=1675969976&id=id&accname=guest&checksum=2B6D238C9B164EB6CD59A8926D2874EC
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. https://doi.org/101164/rccm201908-1581ST [Internet]. 2019 Oct 1 [cited 2023 Feb 42 11];200(7):E45–67. Available from: http://www.atsjournals.org/doi/suppl/10.1164/rccm.201908-1581ST.
Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies. Vol. 75, Anaesthesia. 2020.
Chen Z, Hu J, Liu L, Zhang Y, Liu D, Xiong M, et al. Clinical Characteristics of Patients with Severe and Critical COVID-19 in Wuhan: A Single-Center, Retrospective Study. Infect Dis Ther. 2021 Mar 1;10(1):421–38.
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 28;323(16):1574–81.
Yang Y, Huang Z, Pei Y, Huang Y, Chen C, Zhou T. Clinical Characteristics and Prognostic Factors of Severe COVID-19. Infect Drug Resist. 2025 Jun;Volume 18:3117–25.
Little C, Alsen M, Barlow J, Naymagon L, Tremblay D, Genden E, et al. The Impact of Socioeconomic Status on the Clinical Outcomes of COVID-19; a Retrospective Cohort Study. J Community Health. 2021 Aug 1;46(4):794–802.
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by/4.0/
Atribución 4.0 Internacional (CC BY 4.0)
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0/
Atribución 4.0 Internacional (CC BY 4.0)
http://purl.org/coar/access_right/c_abf2
dc.format.none.fl_str_mv 53 páginas
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Universidad de Caldas
Facultad de Ciencias para la Salud
Colombia
Especialización en Epidemiología
publisher.none.fl_str_mv Universidad de Caldas
Facultad de Ciencias para la Salud
Colombia
Especialización en Epidemiología
institution Universidad de Caldas
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1866404565533851648
spelling Neumonía grave por sars-cov-2: Análisis transversal y de supervivencia en adultos de 18 a 59 años atendidos en la unidad de terapia intensiva de un hospital de tercer nivel en Manizales, Colombia610 - Medicina y salud3. Ciencias Médicas y de la SaludSARS-COV-2NeumoníaCovid-19EpidemiologíaPandemiaMortalidadVirologíaEpidemiologíaAdultoTablas, GráficosMediante el análisis de registros clínicos del SES Hospital Universitario de Caldas se construye una base de datos a partir de la cual se describen las principales características clínicas de los adultos de 18 a 59 años con estancia en terapia intensiva en el contexto de la neumonía grave por sars-cov-2. Se utiliza el programa IBM-SPSS Statistics en su versión 30.0.0.0 licenciado a la Universidad de Caldas para calcular las funciones de supervivencia en un periodo de observación de 28 días, se realiza un análisis bivariado en busca de factores de riesgo asociados a mortalidad y se compara la distribución de variables entre el grupo de sobrevivientes y no sobrevivientes. La supervivencia a la estancia en terapia intensiva fue del 60 % a los 28 días de ingreso y la estancia promedio fue de 12,8 días. No se obtuvo significancia estadística en el análisis bivariado. Se comparan las funciones de supervivencia entre pacientes que difieren por la presencia de una comorbilidad, una intervención o un hallazgo de laboratorio. Acorde con lo reportado en la literatura se evidencia que la hiperlactatemia, la injuria renal aguda, el shock séptico y los estados pro trombóticos confieren un peor pronóstico. Son necesarios estudios de mayor tamaño y poder estadístico que permitan determinar en detalle los predictores de peores desenlaces y estratificar el riesgo de muerte a corto plazo para dirigir acciones a los protocolos de atención al paciente críticamente enfermo en el contexto de la neumonía grave por sars-cov-2.By analysing electronic medical records from the SES University Hospital of Caldas, a database is constructed and explored using IBM-SPSS Statistics software to describe the main clinical characteristics and estimate survival at 28 days of hospital stay for patients aged between 18 and 59 years admitted with severe covid-19 pneumonia to the intensive care unit. A bivariate analysis was performed to identify risk factors associated with mortality, and the distribution of variables was compared between survivors and non-survivors groups. Survival at intensive care unit was 60% at 28 days after admission, and the average length of stay was 12.8 days. Non statistical significance was obtained in the bivariate analysis. Survival functions were compared between patients who differed in terms of comorbidity, intervention, or laboratory findings. Consistent with previous reports, hyperlactataemia, acute kidney injury, septic shock, and prothrombotic states were found to confer a worse prognosis. Future studies with larger populations are needed to determine in detail the predictors of worse outcomes and stratify the risk of short-term death in order to guide actions in the clinical protocols for care of critically ill patients in the context of severe SARS-CoV-2 pneumonia.Resumen -- Introducción -- Planteamiento del problema -- Problema -- Pregunta de investigación -- Justificación -- Marco teórico -- Virología del SARS-CoV-2 -- Epidemiología de la infección por SARS-CoV-2 -- Enfermedad por 2019-nCov (covid-19): aspectos clínicos -- Supervivencia a la covid-19 severa -- Definiciones operativas -- Muerte debida a covid-19 -- Caso confirmado de covid-19 -- Caso probable de covid-19 -- Neumonía grave por covid-19 -- Objetivos -- Objetivo general -- Objetivos específicos -- Diseño metodológico -- Tipo de estudio -- Población -- Tiempo de análisis -- Criterios de inclusión -- Criterios de exclusión -- Procesamiento y análisis de la información -- Análisis univariado y bivariado -- Análisis de supervivencia -- Software de análisis de datos -- Consideraciones éticas -- Tabla de operacionalización de variables -- Resultados -- Discusión -- Conclusiones -- Referencias bibliográficas -- Gráficos de Kaplan Meier -- AnexoEspecializaciónTransversal con análisis de supervivenciaEspecialista en EpidemiologíaEpidemiologíaUniversidad de CaldasFacultad de Ciencias para la SaludColombiaEspecialización en EpidemiologíaFranco Betancur, olivaHoyos-Londoño, MonicaBetancurth Loaiza, Diana PaolaOssa Marulanda, Federico2026-04-14T23:34:22Z2026-04-14T23:34:22Z2025-02-06Trabajo de grado - Especializaciónhttp://purl.org/coar/resource_type/c_18wsTextinfo:eu-repo/semantics/reporthttp://purl.org/coar/resource_type/c_93fc53 páginasapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttps://repositorio.ucaldas.edu.co/handle/ucaldas/26800Universidad de CaldasRepositorio institucional de la Universidad de Caldashttps://repositorio.ucaldas.edu.cospaFadaka AO, Remaliah N, Sibuyi S, Bolaji Adewale O, Bakare OO, Akanbi MO, et al. Understanding the epidemiology, pathophysiology, diagnosis and management of SARS-CoV-2. Journal of International Medical Research [Internet]. [cited 2021 Jun 1];48(8):1–23. Available from: https://us.sagepub.com/en-us/nam/open-access-at-sageChina Responds Slowly, and a Pig Disease Becomes a Lethal Epidemic - The New York Times [Internet]. [cited 2021 Jun 23]. Available from: https://www.nytimes.com/2019/12/17/business/china-pigs-african-swine-fever.htmlZhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Internet]. 2020 Mar 12 [cited 2021 Aug 1];579(7798):270. Available from: /pmc/articles/PMC7095418/The origin of COVID: Did people or nature open Pandora’s box at Wuhan? - Bulletin of the Atomic Scientists [Internet]. [cited 2021 Aug 1]. Available from: https://thebulletin.org/2021/05/the-origin-of-covid-did-people-or-nature-open-pandoras-box-at-w uhan/WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet]. [cited 2021 Aug 1]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at -the-media-briefing-on-covid-19---11-march-2020Wang H, Paulson KR, Pease SA, Watson S, Comfort H, Zheng P, et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet [Internet]. 2022 Apr 16 [cited 2022 Jul 24];399(10334):1513–36. Available from: http://www.thelancet.com/article/S0140673621027963/fulltextSchmidt C. COVID-19 long haulers. Nat Biotechnol [Internet]. 2021 Jul 13 [cited 2021 Aug 1]; Available from: http://www.nature.com/articles/s41587-021-00984-7Sun C, Dyer S, Salvia J, Segal L, Levi R. Worse Cardiac Arrest Outcomes During The COVID-19 Pandemic In Boston Can Be Attributed To Patient Reluctance To Seek Care. https://doi.org/101377/hlthaff202100250. 2021 May 26;40(6):886–95.Vista de Carta desde mi ventana Una fatalista reflexión pandémica [Internet]. [cited 2021 Aug 1]. Available from: https://revistas.uis.edu.co/index.php/revistasaluduis/article/view/11554/11068Tackling the mental health impact of the COVID-19 crisis: An integrated, whole-of-society response [Internet]. [cited 2021 Aug 1]. Available from: https://www.oecd.org/coronavirus/policy-responses/tackling-the-mental-health-impact-of-the-cov id-19-crisis-an-integrated-whole-of-society-response-0ccafa0b/O’Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 2020 590:7844 [Internet]. 2020 Nov 2 [cited 2022 Jul 24];590(7844):140–5. Available from: https://www.nature.com/articles/s41586-020-2918-0Russell TW, Hellewell J, Jarvis CI, Zandvoort K Van, Abbott S, Ratnayake R, et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. Eurosurveillance [Internet]. 2020 Mar 26 [cited 2022 Jul 30];25(12):2000256. Available from: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.12.2000256Staerk C, Wistuba T, Mayr A. Estimating effective infection fatality rates during the course of the COVID-19 pandemic in Germany. BMC Public Health [Internet]. 2021 Dec 1 [cited 2022 Aug 15];21(1). Available from: /pmc/articles/PMC8178670/Marschner IC. Estimating age-specific COVID-19 fatality risk and time to death by comparing population diagnosis and death patterns: Australian data. BMC Medical Research Methodology 2021 21:1 [Internet]. 2021 Jun 21 [cited 2022 Jul 30];21(1):1–10. Available from: https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-021-01314-wHong D, Lee S, Choi YJ, Moon S, Jang Y, Cho YM, et al. The age-standardized incidence, mortality, and case fatality rates of COVID-19 in 79 countries: a cross-sectional comparison and their correlations with associated factors. Epidemiol Health [Internet]. 2021 [cited 2023 Feb 15];43. Available from: /pmc/articles/PMC8611321/Team F. Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. The Lancet [Internet]. 2022 Apr 16 [cited 2023 Feb 15];399(10334):1469–88. Available from: http://www.thelancet.com/article/S0140673621028671/fulltextPastorino R, Pezzullo AM, Villani L, Causio FA, Axfors C, Contopoulos-Ioannidis DG, et al. Change in age distribution of COVID-19 deaths with the introduction of COVID-19 vaccination. Environ Res [Internet]. 2022 Mar 1 [cited 2022 Jul 14];204(Pt C). Available from: https://pubmed.ncbi.nlm.nih.gov/34748775/Mattar S, Martinez-Bravo C, Rivero R, Contreras H, Faccini-Martínez ÁA, Guzman-Teran C, et al. Epidemiological and viral features of a cohort of SARS-CoV-2 symptomatic and asymptomatic individuals in an area of the Colombian Caribbean. Ann Clin Microbiol Antimicrob [Internet]. 2020 [cited 2021 Jun 4];19:58. Available from: https://doi.org/10.1186/s12941-020-00397-5Gautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, et al. Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol [Internet]. 2020;16(12):1159–84. Available from: https://doi.org/10.1080/1744666X.2021.1847640Adams SH, Park MJ, Schaub JP, Brindis CD, Irwin CE. Medical Vulnerability of Young Adults to Severe COVID-19 Illness—Data From the National Health Interview Survey. Journal of Adolescent Health. 2020 Sep 1;67(3):362–8.Shahid Z, Kalayanamitra R, McClafferty B, Kepko D, Ramgobin D, Patel R, et al. COVID-19 and Older Adults: What We Know [Internet]. Vol. 68, Journal of the American Geriatrics Society. Blackwell Publishing Inc.; 2020 [cited 2021 May 9]. p. 926–9. Available from: https://doi.org/10.1038/s41591-020-Ioannidis JPA. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bull World Health Organ. 2021 Jan 1;99(1):19-33F. doi: 10.2471/BLT.20.265892. Epub 2020 Oct 14. PMID: 33716331; PMCID: PMC7947934.Sorci G, Faivre B, Morand S. Explaining among-country variation in COVID-19 case fatality rate. Scientific Reports 2020 10:1 [Internet]. 2020 Nov 3 [cited 2021 Sep 28];10(1):1–11. Available from: https://www.nature.com/articles/s41598-020-75848-2Lu Y, Huang Z, Wang M, Tang K, Wang S, Gao P, et al. Clinical characteristics and predictors of mortality in young adults with severe COVID-19: a retrospective observational study. Ann Clin Microbiol Antimicrob [Internet]. 2021 Dec 1 [cited 2021 May 9];20(1):3. Available from: https://doi.org/10.1186/s12941-020-00412-9Siu YL, Teoh KT, Lo J, Chan CM, Kien F, Escriou N, Tsao SW, Nicholls JM, Altmeyer R, Peiris JS, Bruzzone R, Nal B. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J Virol [Internet]. 2008 Nov 15 [cited 2021 Aug 19];82(22):11318–30. Available from: https://pubmed.ncbi.nlm.nih.gov/18753196/Tracking SARS-CoV-2 variants [Internet]. [cited 2021 Aug 19]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A, Kimura I, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 2022 603:7902 [Internet]. 2022 Feb 1 [cited 2023 Feb 4];603(7902):706–14. Available from: https://www.nature.com/articles/s41586-022-04474-xPlotkin S, Robinson JM, Cunningham G, Iqbal R, Larsen S. The complexity and cost of vaccine manufacturing - An overview. Vaccine [Internet]. 2017 Jul 24 [cited 2021 Sep 29];35(33):4064–71. Available from: https://pubmed.ncbi.nlm.nih.gov/28647170/Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, De Ridder D, Petrovic D, Schrempft S, Marcus K, Yerly S, Arm Vernez I, Keiser O, Hurst S, Posfay-Barbe KM, Trono D, Pittet D, Gétaz L, Chappuis F, Eckerle I, Vuilleumier N, Meyer B, Flahault A, Kaiser L, Guessous I. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet [Internet]. 2020 Aug 1 [cited 2021 Aug 31];396(10247):313–9. Available from: https://pubmed.ncbi.nlm.nih.gov/32534626/Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med [Internet]. 2021 Jan 1 [cited 2021 Sep 29];174(1):69–79. Available from: https://pubmed.ncbi.nlm.nih.gov/32941052/Wong SCY, Kwong RT, Wu TC, Chan JWM, Chu MY, Lee SY, Wong HY, Lung DC. Risk of nosocomial transmission of coronavirus disease 2019: an experience in a general ward setting in 40 Hong Kong. J Hosp Infect [Internet]. 2020 Jun 1 [cited 2021 Sep 29];105(2):119–27. Available from: https://pubmed.ncbi.nlm.nih.gov/32259546/Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis [Internet]. 2020 Aug 1 [cited 2021 Sep 1];71(15):732–9. Available from: https://pubmed.ncbi.nlm.nih.gov/32150618/Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. https://doi.org/101056/NEJMoa2012410 [Internet]. 2020 May 7 [cited 2021 Sep 30];382(25):2411–8. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa2012410Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA [Internet]. 2020 Jun 23 [cited 2021 Sep 1];323(24):2493–502. Available from: https://jamanetwork.com/journals/jama/fullarticle/2766117Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci [Internet]. 2020 [cited 2021 Sep 29];50(SI-1):611–9. Available from: https://pubmed.ncbi.nlm.nih.gov/32293834/JP J. Monoclonal Antibody for Patients with Covid-19. N Engl J Med [Internet]. 2021 Mar 25 [cited 2021 Sep 29];384(12):1170–1. Available from: https://pubmed.ncbi.nlm.nih.gov/33534967/Spinner CD, Gottlieb RL, Criner GJ, López JRA, Cattelan AM, Viladomiu AS, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA [Internet]. 2020 Sep 15 [cited 2021 Sep 29];324(11):1048–57. Available from: https://jamanetwork.com/journals/jama/fullarticle/2769871Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study - Merck.com [Internet]. [cited 2021 Oct 11]. Available from: https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-re duced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-forpatients-with-mild-or-moderat/Zhang J, Rao X, Li Y, Zhu Y, Liu F, Guo G, et al. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. Ann Intensive Care [Internet]. 2021 Dec 1 [cited 2022 Jan 10];11(1). Available from: https://pubmed.ncbi.nlm.nih.gov/33420963/Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med [Internet]. 2020 Mar 1 [cited 2021 Dec 14];8(3):267–76. Available from: https://pubmed.ncbi.nlm.nih.gov/32043986/Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med [Internet]. 2021 Mar 18 [cited 2022 Jan 10];384(11):1015–27. Available from: https://pubmed.ncbi.nlm.nih.gov/33523609/Bewick V, Cheek L, Ball J. Statistics review 12: Survival analysis. Crit Care [Internet]. 2004 Oct [cited 2023 Feb 21];8(5):389. Available from: /pmc/articles/PMC1065034/Horwitz LI, Jones SA, Cerfolio RJ, Francois F, Greco J, Rudy B, et al. Trends in COVID-19 Risk-Adjusted Mortality Rates. J Hosp Med [Internet]. 2021 Feb 1 [cited 2023 Feb 6];16(2):90–2. Available from: https://pubmed.ncbi.nlm.nih.gov/33147129/Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Intern Med [Internet]. 2020 Nov 1 [cited 2023 Feb 6];180(11):1436–47. Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2768602Kreier F. Wide-ranging genetic study of severe COVID finds common risk factors. Nature [Internet]. 2022 Mar 10 [cited 2022 Mar 22]; Available from: https://www.nature.com/articles/d41586-022-00677-4Changing the COVID-19 Case Definition - UK Health Security Agency [Internet]. [cited 2022 Feb 5]. Available from: https://ukhsa.blog.gov.uk/2022/02/04/changing-the-covid-19-case-definition/Edwin F, Alvarado P, Milena S, Fuentes A, Malo DC, Leidy S, et al. Instituto Nacional de Salud. Anexo. Instructivo para la vigilancia en salud pública intensificada de infección respiratoria aguda asociada al nuevo coronavirus 2019 (COVID-19) [Internet]. 2020 [cited 2021 Apr 18]. Available from: https://www.atlantico.gov.co/images/stories/adjuntos/ salud/1-Anexo__Instructivo_COVID.pdf.Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nature Medicine 2022 28:8 [Internet]. 2022 Jul 25 [cited 2023 Feb 7];28(8):1706–14. Available from: https://www.nature.com/articles/s41591-022-01909-wWho, HQ, Ddi, Dna, Cat. INTERNATIONAL GUIDELINES FOR CERTIFICATION AND CLASSIFICATION (CODING) OF COVID-19 AS CAUSE OF DEATH Based on ICD International Statistical Classification of Diseases.Corman Victor M, Landt Olfert, Kaiser Marco, Molenkamp Richard, Meijer Adam, Chu Daniel KW. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;… [Internet]. [cited 2023 Feb 8]. Available from: https://www.eurosurveillance.org/docserver/fulltext/eurosurveillance/25/3/eurosurv-25-35.pdf?e xpires=1675969976&id=id&accname=guest&checksum=2B6D238C9B164EB6CD59A8926D2874ECMetlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. https://doi.org/101164/rccm201908-1581ST [Internet]. 2019 Oct 1 [cited 2023 Feb 42 11];200(7):E45–67. Available from: http://www.atsjournals.org/doi/suppl/10.1164/rccm.201908-1581ST.Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies. Vol. 75, Anaesthesia. 2020.Chen Z, Hu J, Liu L, Zhang Y, Liu D, Xiong M, et al. Clinical Characteristics of Patients with Severe and Critical COVID-19 in Wuhan: A Single-Center, Retrospective Study. Infect Dis Ther. 2021 Mar 1;10(1):421–38.Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 28;323(16):1574–81.Yang Y, Huang Z, Pei Y, Huang Y, Chen C, Zhou T. Clinical Characteristics and Prognostic Factors of Severe COVID-19. Infect Drug Resist. 2025 Jun;Volume 18:3117–25.Little C, Alsen M, Barlow J, Naymagon L, Tremblay D, Genden E, et al. The Impact of Socioeconomic Status on the Clinical Outcomes of COVID-19; a Retrospective Cohort Study. J Community Health. 2021 Aug 1;46(4):794–802.https://creativecommons.org/licenses/by/4.0/Atribución 4.0 Internacional (CC BY 4.0)http://purl.org/coar/access_right/c_abf2oai:repositorio.ucaldas.edu.co:ucaldas/268002026-04-15T08:01:46Z

Publicaciones similares